8-K: MIRA Pharmaceuticals Appoints Alan Weichselbaum as CFO, Announces Departure of Michelle Yanez

MIRA Pharmaceuticals announced the appointment of Alan Weichselbaum as Chief Financial Officer, effective May 15, 2025, following the mutual separation of Michelle Yanez from the same role.

Summary

• MIRA Pharmaceuticals announced that Michelle Yanez has mutually agreed to step down from her position as Chief Financial Officer, Treasurer, and Secretary, effective May 16, 2025.
• Alan Weichselbaum has been appointed as the new Chief Financial Officer, effective May 15, 2025.
• Mr. Weichselbaum brings over 30 years of experience in corporate finance, capital markets, and strategic advisory.
• He will receive an annual salary of $60,000 and is eligible for options to purchase 75,000 shares of the company's common stock.
• 37,500 of the options will vest six months after the start date (May 19, 2025), and the remaining 37,500 will vest twelve months after the start date, contingent upon continued employment.
• Mr. Weichselbaum's employment is on an at-will basis.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the appointment of an experienced CFO, but tempered by the mutual departure of the previous CFO and the relatively low base salary.

Positives

• The appointment of Alan Weichselbaum brings significant financial expertise and experience to MIRA Pharmaceuticals.
• Weichselbaum's background includes experience in corporate finance, capital markets, and strategic advisory.
• The compensation package includes stock options, aligning his interests with the company's long-term success.
• Weichselbaum's experience as a director of FinWise Bancorp and CFO of Telomir Pharmaceuticals adds credibility.

Negatives

• The departure of Michelle Yanez as CFO, although mutual, creates a transition period.
• The base salary of $60,000 may be considered relatively low for a CFO position, potentially indicating a part-time or consulting arrangement.
• The role is part-time, requiring 20 hours per week, which may limit the CFO's availability and involvement.

Risks

• The at-will employment agreement allows for termination by either party at any time, creating potential instability.
• The vesting of stock options is contingent upon continued employment, which could be a risk if Weichselbaum leaves the company before the vesting dates.
• The success of Weichselbaum in the role depends on his ability to balance his responsibilities at MIRA Pharmaceuticals with his other commitments, including his roles at Telomir Pharmaceuticals and The Wexus Group.

Future Outlook

The company anticipates that Alan Weichselbaum will play a key leadership role in advancing the financial and strategic objectives of the company as it pursues growth through drug development, licensing, and potential M&A opportunities.

Management Comments

• Alan Weichselbaum's deep financial acumen, combined with extensive experience in investor relations, capital formation, and M&A, makes him a vital member of the executive leadership at MIRA Pharmaceuticals, Inc.

Industry Context

The appointment of a new CFO is a common occurrence in the pharmaceutical industry, especially for companies undergoing growth or strategic changes. The focus on drug development, licensing, and potential M&A opportunities suggests that MIRA Pharmaceuticals is positioning itself for expansion and requires strong financial leadership.

Comparison to Industry Standards

• CFO compensation in the pharmaceutical industry varies widely depending on the size and stage of the company.
• For a small-cap company like MIRA Pharmaceuticals, a base salary of $60,000 may be lower than the average for a full-time CFO, but the addition of stock options can provide significant upside potential.
• Comparable companies might include other small-cap pharmaceutical firms focused on drug development and licensing, such as Telomir Pharmaceuticals, where Weichselbaum also serves as CFO.

Management Changes

Stakeholder Impact

• Shareholders may view the appointment of a new CFO with significant experience positively.
• Employees may experience a period of adjustment during the transition.
• The change in CFO could impact the company's financial strategies and relationships with investors and creditors.

Next Steps

• Alan Weichselbaum will assume his responsibilities as CFO on May 19, 2025.
• The Board of Directors will determine the exercise price for the stock options granted to Alan Weichselbaum.
• The company will continue to pursue growth through drug development, licensing, and potential M&A opportunities.

Key Dates

Keywords

Chief Financial Officer, CFO, Alan Weichselbaum, Michelle Yanez, MIRA Pharmaceuticals, Appointment, Resignation, Employment Agreement, Stock Options, Compensation